MicroRNA-122 mimic transfection contributes to apoptosis in HepG2 cells

Hongyan Huang1, Yueyong Zhu1, Shaoyang Li2

  • 1Liver Diseases Research Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, P.R. China.

Molecular Medicine Reports
|September 2, 2015
PubMed

Insights

MicroRNA-122 (miR-122) restoration can induce cancer cell death in hepatocellular carcinoma (HCC) models. This study shows miR-122 mimic transfection increases apoptosis in HCC cells by targeting Bcl-w and activating caspases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Hepatocellular carcinoma (HCC) is a major cause of cancer mortality.
  • MicroRNA-122 (miR-122) is downregulated in HCC and represses Bcl-w, an apoptosis regulator.
  • Restoring miR-122 may offer a therapeutic strategy for HCC.

Purpose of the Study:

  • To investigate the role and therapeutic potential of miR-122 in HCC.
  • To determine if miR-122 activation induces selective hepatocellular apoptosis via caspase activation.

Main Methods:

  • Transfection of HepG2 cells with an miR-122 mimic.
  • Assessing apoptotic rates using assays.
  • Analyzing Bcl-w, caspase-9, and caspase-3 mRNA levels via RT-PCR.
  • Confirming protein expression trends with immunocytochemistry.

Main Results:

  • miR-122 mimic transfection significantly increased HepG2 cell apoptosis.
  • Bcl-w mRNA levels were significantly reduced post-transfection.
  • mRNA levels of caspase-9 and caspase-3 were markedly increased.
  • Immunocytochemistry results corroborated the observed mRNA trends.

Conclusions:

  • Endogenous miR-122 contributes to apoptosis in HepG2 cells.
  • Transfecting with an miR-122 mimic normalizes apoptotic levels in an HCC model.
  • miR-122 holds potential as a therapeutic agent for hepatocellular carcinoma.